Results of galmed's phase 2b arrest trial of aramchol published in nature medicine

Tel aviv, israel, october 11, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol in patients with nash have been published in nature medicine (https://www.nature.com/articles/s41591-021-01495-3).
GLMD Ratings Summary
GLMD Quant Ranking